VIPoma other diagnostic studies: Difference between revisions
Jump to navigation
Jump to search
Madhu Sigdel (talk | contribs) No edit summary |
m Bot: Removing from Primary care |
||
| (8 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{VIPoma}} | {{VIPoma}} | ||
{{CMG}}; {{AE}}{{MSI}} | {{CMG}}; {{AE}}{{MSI}}{{Homa}} | ||
==Overview== | ==Overview== | ||
Other diagnostic studies for VIPoma include immunohistochemical staining test, which demonstrates staining for markers such as | Other [[diagnostic studies]] for VIPoma include immunohistochemical staining test, which demonstrates staining for markers such as [[chromogranin A]], [[Cytokeratin|cytokeratin 19]], [[synaptophysin]], [[Ki-67]], [[Enolase|neuron specific enolase]], PGP 9.5. | ||
==Other Diagnostic Studies== | ==Other Diagnostic Studies== | ||
*Immunohistochemical staining may be helpful in the diagnosis of VIPoma. Findings suggestive of VIPoma include positive histochemical staining for: | *Immunohistochemical staining may be helpful in the diagnosis of VIPoma. Findings suggestive of VIPoma include positive histochemical staining for:<ref name="pmid18684027">{{cite journal| author=Chetty R| title=An overview of practical issues in the diagnosis of gastroenteropancreatic neuroendocrine pathology. | journal=Arch Pathol Lab Med | year= 2008 | volume= 132 | issue= 8 | pages= 1285-9 | pmid=18684027 | doi=10.1043/1543-2165(2008)132[1285:AOOPII]2.0.CO;2 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18684027 }}</ref> | ||
**[[Chromogranin A]] | |||
**[[Cytokeratin|Cytokeratin 19]] positive stain is an independent marker of aggressive behavior in pancreatic [[neuroendocrine tumors]]. | |||
** | **[[Synaptophysin]] | ||
**Ki-67 (indicates the percentage of neoplastic cells immunolabeled for the marker of proliferation Ki67) | **[[Ki-67]] (indicates the percentage of [[Neoplasia|neoplastic cells]] immunolabeled for the marker of proliferation Ki67) | ||
**NSE (neuron-specific enolase) | **NSE [[Enolase|(neuron-specific enolase]]) | ||
**PGP 9.5 (protein gene product 9.5) | **PGP 9.5 (protein gene product 9.5) | ||
| Line 21: | Line 21: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category: | |||
[[Category:Medicine]] | |||
[[Category:Oncology]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Endocrinology]] | |||
[[Category:Gastroenterology]] | |||
Latest revision as of 00:40, 30 July 2020
|
VIPoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
VIPoma other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of VIPoma other diagnostic studies |
|
Risk calculators and risk factors for VIPoma other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Madhu Sigdel M.B.B.S.[2] Homa Najafi, M.D.[3]
Overview
Other diagnostic studies for VIPoma include immunohistochemical staining test, which demonstrates staining for markers such as chromogranin A, cytokeratin 19, synaptophysin, Ki-67, neuron specific enolase, PGP 9.5.
Other Diagnostic Studies
- Immunohistochemical staining may be helpful in the diagnosis of VIPoma. Findings suggestive of VIPoma include positive histochemical staining for:[1]
- Chromogranin A
- Cytokeratin 19 positive stain is an independent marker of aggressive behavior in pancreatic neuroendocrine tumors.
- Synaptophysin
- Ki-67 (indicates the percentage of neoplastic cells immunolabeled for the marker of proliferation Ki67)
- NSE (neuron-specific enolase)
- PGP 9.5 (protein gene product 9.5)
References
- ↑ Chetty R (2008). "An overview of practical issues in the diagnosis of gastroenteropancreatic neuroendocrine pathology". Arch Pathol Lab Med. 132 (8): 1285–9. doi:10.1043/1543-2165(2008)132[1285:AOOPII]2.0.CO;2. PMID 18684027.